Form 4 for SYRE Spyre Therapeutics, Inc.
Accepted 2026-02-04 00:00:00 ET · period of report 2026-02-02 · accession 0001758363-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-04 | 2026-02-02 | SYRE | Turtle Cameron | CEO, Dir | S - Sale | $32.80 | -15.0K | 657.5K | -2% | -$492.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-02-02 | S | D | 957 | $31.82 | 671,583 | D | — | — | (F2) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.42 to $32.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range. (F4) Includes 633 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on August 15, 2024. (F3) Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. |
| 2 | Common | Common Stock | 2026-02-02 | S | D | 14,043 | $32.87 | 657,540 | D | — | — | (F5) The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.48 to $33.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range. (F3) Includes 145,198 shares of common stock that vest in monthly installments over approximately one year, subject to the continuing service of the Reporting Person on each vesting date. |